Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion

Coronary Artery Disease

Volumn 17, Issue 5, 2006, Pages 463-469

  Zhao, Jing Lin ^a   Yang, Yue Jin ^a   You, Shi Jie ^a   Jing, Zhi Cheng ^a   Wu, Yong Jian ^a   Cheng, Ji Lin ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Fosinopril; No reflow; Valsartan

Indexed keywords

ADENOSINE TRIPHOSPHATE; FOSINOPRIL; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; KIR6.1 CHANNEL; POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR 2; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART INFARCTION; HEART VENTRICLE FUNCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZATION; REPERFUSION; SWINE; TIME; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; CHEMOPREVENTION; ENDOTHELIUM; FOSINOPRIL; H(+)-K(+)-EXCHANGING ATPASE; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; SWINE; TETRAZOLES; TIME FACTORS; VALINE;

EID: 33748197695     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200608000-00010     Document Type: Article

References (33)

1. Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 1999; 138:188-202.
2. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993-1999.
3. van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. Lancet 1997; 350:615-619.
4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no-reflow' phenomenon: a predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction. Circulation 1996; 93:223-228.
5. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97:765-772.
6. Swinburn JM, Lahiri A, Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction. J Am Coll Cardiol 2001; 38:19-25.
7. Reffelmann T, Kloner RA. The 'no-reflow' phenomenon: basic science and clinical correlates. Heart 2002; 87:162-168.
8. Endoh A, Miura T, Iimura O. Does delayed no-reflow phenomenon cause myocardial necrosis? J Cardiovasc Pathol 1993; 2:225-230.
9. Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111:98-111.
10. Humphrey SM, Gavin JB, Herdson PB. The relationship of ischemic contracture to vascular reperfusion in the isolated rat heart. J Mol Cell Cardiol 1980; 12:1397-1406.
11. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello M. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol 1994; 266:H1541-H1550.
12. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54:1496-1508.
13. Tiefenbacher CP, Friedrich S, Bleeke T, Vahl C, Chen X, Niroomand F, et al. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 2004; 286:H1425-H1432.
14. Tavli T, Gocer H. Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. Jpn Heart J 2002; 43:667-674.
15. Guan S, Wang B. Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells. Chin Med J (Engl) 2003; 116:923-927.
16. Sun YP, Zhu BQ, Browne AE, Pulukurthy S, Chou TM, Sudhir K, et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001; 6:175-181.
17. Gande S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K (ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002; 40:1339-1346.
18. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
21. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001; 37:1056-1061.
22. Maruyama R, Hatta E, Yasuda K, Smith NC, Levi R. Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors. J Pharmacol Exp Ther 2000; 294:248-254.
23. Wagner A, Herkner H, Schreiber W, Bur A, Woisetschlager C, Stix G, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb Haemost 2002; 88:180-185.
24. Podesser BK, Schirnhofer J, Bernecker OY, Kroner A, Franz M, Semsroth S, et al. Optimizing ischemia/reperfusion in the failing rat heart: improved myocardial protection with acute ACE inhibition. Circulation 2002; 106 (suppl 1):I277-I283.
25. O'Rourke B. Myocardial K (ATP) channels in preconditioning. Circ Res 2000; 87:845-855.
26. Bernardo NL, D'Angelo M, Okubo S, Joy A, Kukreja RC. Delayed ischemic preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit heart. Am J Physiol 1999; 276:H1323-H1330.
27. Jugdutt BI, Sawicki G. AT1receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics. Mol Cell Biochem 2004; 263:179-188.
28. Sawicki G, Menon V, Jugdutt BI. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Cardiovasc Fail 2004; 10:442-449.
29. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Longterm Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332:80-85.
30. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction (CCS21). Lancet 1995; 345:686-687.
31. Pfeffer MA. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000; 139:S23-S28.
32. Swinburn JM, Lahiri A, Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dyssynergic myocardium early after acute myocardial infarction. J Am Coll Cardiol 2001; 38:19-25.
33. Coggins MP, Sklenar J, Le DE, Wei K, Lindner JR, Kaul S, et al. Noninvasive prediction of ultimate infarct size at the time of acute coronary occlusion based on the extent and magnitude of collateral-derived myocardial blood flow. Circulation 2001; 104:2471-2477.